Sandoz, Accord Confirm First US Aubagio Generics, As Settlement Day Arrives
Accord’s Product ‘Is Ready To Ship,’ Dozen ANDA Sponsors In Place To Launch
Viatris’ Mylan and Teva are among firms holding approved ANDAs for generic Aubagio, as the product falls to generic competition in the US.
You may also be interested in...
Sandoz Unveils $400m+ Investment In Slovenian Biosimilars Plant
Spurred on by “increasing global demand for biosimilar medicines,” Sandoz has revealed plans to invest at least $400m in building a new biologics production plant in Slovenia.
ANDA Sponsors Silent As Novartis Confirms US Gilenya Generic Entries
One of the largest small molecule opportunities in the US, Novartis’s Gilenya to treat relapsing-remitting multiple sclerosis, now has generic competition, the originator has confirmed following a series of favorable court rulings for ANDA sponsors.
Dr Reddy’s Can Still Go It Alone After Penning Orencia Biosimilar Deal
Targeting a dual biologic for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis, Coya Therapeutics has joined forces with abatacept biosimilar developer Dr Reddy’s.